Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021...
June 23 2021 - 7:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced a
comprehensive update on its discovery and clinical-stage pipeline
at its 2021 virtual R&D Day. Presentations will highlight
Jounce’s productive discovery engine and platform, updates on its
discovery pipeline, and progress on the clinical development of
JTX-8064. In addition to presentations from Jounce management and
scientific team members, key opinion leader and one of Jounce’s
scientific founders, Robert Schreiber, Ph.D., Distinguished
Professor of Pathology and Immunology at The Washington University
School of Medicine, will discuss the scientific rationale for
targeting myeloid cells and the therapeutic potential of
re-programming macrophages through inhibition of LILRB2.
“Jounce is at an exciting time in its life cycle and I am
incredibly pleased to have the opportunity to share the latest
developments on our discovery and clinical stage pipelines, while
also sharing a look into our productive and validated Translational
Science Platform. More specifically, we will discuss the
monotherapy dose escalation status of our INNATE trial of JTX-8064.
Thanks to a high level of investigator engagement and dedicated
efforts from our team, the timing of expansion cohort initiations
is now expected in the third quarter of this year,” said Richard
Murray, Ph.D., Chief Executive Officer and President of Jounce
Therapeutics. “Our pipeline has been built to bring forward new
biomarker-enabled immunotherapies to address the evolving unmet
needs of cancer patients, whose tumors may be sensitive or
resistant to today’s approved immunotherapies.”
“One of the key attributes of Jounce’s approach to
immuno-oncology is its expertise in developing molecules that
target a diverse set of immune cell types within the tumor
microenvironment. Through the work of our platform, we have a
greater understanding of how immune suppressive macrophages and
LILRB2 itself can serve as negative prognostic indicators in
several tumor types,” said Dmitri Wiederschain, Ph.D., Chief
Scientific Officer of Jounce Therapeutics. “We believe that the
LILRB family represents attractive immuno-oncology targets with the
potential to improve upon and restore responsiveness to PD-(L)1
inhibitors. As such, we are pleased to announce that we are rapidly
advancing two additional LILRB family programs through discovery,
targeting LILRB1 and LILRB4.”
R&D Day Presentation Highlights
Include:
- Utilization of Jounce’s Translational Science Platform to
investigate the tumor microenvironment and identify cell
type-specific targets with unique biology
- Overview of differentiated biomarker approach from discovery
through development
- Introduction of new discovery programs focused on additional
LILRB family members, including LILRB1 and LILRB4
- Update on monotherapy dose escalation and receptor occupancy
from the INNATE clinical trial of JTX-8064
- Announcement of timing of INNATE clinical trial monotherapy and
pimivalimab combination expansion cohort initiation, expected in
the third quarter of 2021
- Update on continued progress on Jounce’s first biomarker
patient selection study, SELECT
Anticipated Milestones:
- JTX-8064 (INNATE):
- Establish recommended Phase 2 dose
- Initiate tumor-specific monotherapy and pimivalimab combination
expansion cohorts beginning in the third quarter of 2021
- Vopratelimab (SELECT):
- Patient enrollment to support clinical data in 2022
- Continue to advance multiple new targets through discovery
pipeline with goal of an investigational new drug (IND) every 12-18
months
Webcast Details:A webcast of the R&D Day
will be available by visiting “Events and Presentations” in the
Investors and Media section of Jounce’s website at
www.jouncetx.com. A replay of the webcast will be available for 30
days following the presentation.
About Jounce Therapeutics:Jounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
currently has multiple development stage programs ongoing while
simultaneously advancing additional early-stage assets from its
robust discovery engine based on its Translational Science
Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2
(ILT4) receptor antagonist shown to reprogram immune-suppressive
tumor associated macrophages to an anti-tumor state in preclinical
studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a
monotherapy and in combination with pimivalimab (formerly
JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling
patients with advanced solid tumors. Jounce’s most advanced product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS, and is currently being studied in the SELECT Phase
2 trial. Pimivalimab is a PD-1 inhibitor intended for combination
use in the INNATE and SELECT trials and with Jounce’s broader
pipeline. Additionally, Jounce obtained IND clearance for and
exclusively licensed worldwide rights to JTX-1811, a monoclonal
antibody targeting CCR8 and designed to selectively deplete T
regulatory cells in the tumor microenvironment, to Gilead Sciences,
Inc. For more information, please visit www.jouncetx.com.
Cautionary Note Regarding
Forward-Looking Statements:Various statements in this
release concerning Jounce’s future expectations and prospects,
including without limitation, Jounce’s expectations regarding the
timing, initiation, progress, results and release of data for
clinical trials of JTX-8064, vopratelimab and pimivalimab;
establishment of a recommended Phase 2 dose for JTX-8064; the
timing, progress and results of discovery programs and preclinical
studies for any future product candidates; the potential benefits
of any of these product candidates; our analyses and plans for data
disclosures, and our plans and expectations in light of the
COVID-19 pandemic, may constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 and other federal
securities laws and are subject to substantial risks, uncertainties
and assumptions. You should not place reliance on these
forward-looking statements, which often include words such as “look
forward”, “may” or similar terms, variations of such terms or the
negative of those terms. Although Jounce believes that the
expectations reflected in the forward-looking statements are
reasonable, Jounce cannot guarantee such outcomes. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including,
without limitation, Jounce’s ability to successfully demonstrate
the efficacy and safety of its product candidates and future
product candidates; the preclinical and clinical results for its
product candidates, which may not support further development and
marketing approval; the potential advantages of Jounce’s product
candidates; Jounce’s ability to successfully manage its clinical
trials; the development plans of its product candidates and any
companion or complementary diagnostics; actions of regulatory
agencies, which may affect the initiation, timing and progress of
clinical trials of Jounce’s product candidates; and those risks
more fully discussed in the section entitled “Risk Factors” in
Jounce’s most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission as well as discussions of
potential risks, uncertainties, and other important factors in
Jounce’s subsequent filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
Jounce undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor and Media Contacts:Mark YoreJounce
Therapeutics, Inc.+1-857-200-1255 myore@jouncetx.com
Julie SeidelStern Investor
Relations+1-212-362-1200Julie.Seidel@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From May 2023 to May 2024